$YTENQ
YIELD10 BIOSCIENCE, INC.

2018 Q3 Form 10-Q Financial Statement

#000112170218000031 Filed on August 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q2 2017 Q2
Revenue $76.00K $285.0K $293.0K
YoY Change -65.92% -2.73% 55.85%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.417M $1.456M $1.866M
YoY Change 32.06% -21.97% 62.4%
% of Gross Profit
Research & Development $1.340M $1.260M $1.140M
YoY Change 18.58% 10.53% -26.45%
% of Gross Profit
Depreciation & Amortization $50.00K $50.00K $60.00K
YoY Change 0.0% -16.67% -60.0%
% of Gross Profit
Operating Expenses $1.417M $1.456M $1.866M
YoY Change 32.06% -21.97% 62.4%
Operating Profit -$2.676M -$2.431M -$2.711M
YoY Change 35.02% -10.33% 8.09%
Interest Expense -$20.00K
YoY Change -2100.0%
% of Operating Profit
Other Income/Expense, Net $38.00K $38.00K -$16.00K
YoY Change -188.37% -337.5% -1700.0%
Pretax Income -$2.640M -$2.390M -$2.730M
YoY Change 30.37% -12.45% 8.76%
Income Tax
% Of Pretax Income
Net Earnings -$2.638M -$2.393M -$2.730M
YoY Change 29.95% -12.34% -14.69%
Net Earnings / Revenue -3471.05% -839.65% -931.74%
Basic Earnings Per Share
Diluted Earnings Per Share -$10.56M -$9.560M -$39.00M
COMMON SHARES
Basic Shares Outstanding 10.01M shares 9.968M shares 28.50M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.800M $9.700M $3.000M
YoY Change 160.0% 223.33% -18.92%
Cash & Equivalents $3.306M $3.168M $3.011M
Short-Term Investments $4.500M $6.500M
Other Short-Term Assets $400.0K $400.0K $500.0K
YoY Change 33.33% -20.0% -54.55%
Inventory
Prepaid Expenses
Receivables $54.00K $29.00K $213.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $8.264M $10.10M $3.908M
YoY Change 137.2% 158.55% -30.97%
LONG-TERM ASSETS
Property, Plant & Equipment $1.435M $1.477M $1.633M
YoY Change -9.58% -9.55% -36.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $106.0K $98.00K $95.00K
YoY Change 53.62% 3.16% -86.75%
Total Long-Term Assets $1.873M $7.116M $2.160M
YoY Change -10.3% 229.44% -42.03%
TOTAL ASSETS
Total Short-Term Assets $8.264M $10.10M $3.908M
Total Long-Term Assets $1.873M $7.116M $2.160M
Total Assets $10.14M $17.22M $6.068M
YoY Change 81.93% 183.78% -35.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $39.00K $34.00K $70.00K
YoY Change -18.75% -51.43% -95.23%
Accrued Expenses $1.770M $871.0K $2.689M
YoY Change -8.67% -67.61% 58.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.809M $1.489M $2.759M
YoY Change -8.91% -46.03% -31.88%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.000M $900.0K $1.100M
YoY Change 0.0% -18.18% -7.95%
Total Long-Term Liabilities $1.000M $900.0K $1.100M
YoY Change 0.0% -18.18% -7.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.809M $1.489M $2.759M
Total Long-Term Liabilities $1.000M $900.0K $1.100M
Total Liabilities $2.809M $2.430M $3.827M
YoY Change -7.08% -36.5% -27.04%
SHAREHOLDERS EQUITY
Retained Earnings -$350.1M -$347.4M -$338.2M
YoY Change 2.9% 2.74% 0.81%
Common Stock $357.5M $357.1M $340.5M
YoY Change 4.28% 4.88% 0.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.315M $9.576M $2.241M
YoY Change
Total Liabilities & Shareholders Equity $10.14M $17.22M $6.068M
YoY Change 81.93% 183.78% -35.36%

Cashflow Statement

Concept 2018 Q3 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$2.638M -$2.393M -$2.730M
YoY Change 29.95% -12.34% -14.69%
Depreciation, Depletion And Amortization $50.00K $50.00K $60.00K
YoY Change 0.0% -16.67% -60.0%
Cash From Operating Activities -$1.840M -$1.860M -$1.860M
YoY Change -8.91% 0.0% 70.64%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$30.00K $0.00
YoY Change 0.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $2.000M -$2.500M $0.00
YoY Change -100.0%
Cash From Investing Activities $1.990M -$2.530M $0.00
YoY Change -20000.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 -10.00K
YoY Change -100.0% -100.0% -96.3%
NET CHANGE
Cash From Operating Activities -1.840M -1.860M -1.860M
Cash From Investing Activities 1.990M -2.530M 0.000
Cash From Financing Activities 0.000 0.000 -10.00K
Net Change In Cash 150.0K -4.390M -1.870M
YoY Change -314.29% 134.76% 19.87%
FREE CASH FLOW
Cash From Operating Activities -$1.840M -$1.860M -$1.860M
Capital Expenditures -$10.00K -$30.00K $0.00
Free Cash Flow -$1.830M -$1.830M -$1.860M
YoY Change -8.96% -1.61% 116.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001121702
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10011395 shares
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Registrant Name
EntityRegistrantName
YIELD10 BIOSCIENCE, INC.
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-12000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
118000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
0 USD
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2017Q3 invest Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
5.04
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
76000 USD
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
34000 USD
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
54000 USD
CY2018Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
29000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2299000 USD
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1455000 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
335000 USD
CY2018Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
213000 USD
CY2017Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
585000 USD
CY2018Q2 us-gaap Accrued Rent Current
AccruedRentCurrent
627000 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-85000 USD
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-99000 USD
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
355431000 USD
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
357013000 USD
CY2017Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
951958 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1029033 shares
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11722414 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11518573 shares
CY2016Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
29622 sqft
CY2017Q4 us-gaap Assets
Assets
16882000 USD
CY2018Q2 us-gaap Assets
Assets
12011000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
14917000 USD
CY2018Q2 us-gaap Assets Current
AssetsCurrent
10104000 USD
CY2018Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
6486 USD
CY2018Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
6486 USD
us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0 USD
us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
0 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14487000 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3168000 USD
CY2018Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
9654000 USD
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7741000 USD
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3443000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14804000 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3500000 USD
CY2018Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
10597486 shares
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12180541 shares
CY2018Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12278694 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-14000 USD
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9089159 shares
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9991977 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9089159 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9991977 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
91000 USD
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
100000 USD
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2725000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4819000 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2400000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4694000 USD
CY2017Q2 us-gaap Costs And Expenses
CostsAndExpenses
3004000 USD
us-gaap Costs And Expenses
CostsAndExpenses
5389000 USD
CY2018Q2 us-gaap Costs And Expenses
CostsAndExpenses
2705000 USD
us-gaap Costs And Expenses
CostsAndExpenses
5072000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
106000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
96000 USD
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.96
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.69
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
646000 USD
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
407000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
-12000 USD
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
-6000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
14000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-42000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
147000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-54000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-165000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-884000 USD
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-1000 USD
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-542000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
56000 USD
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-26000 USD
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-22000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
3380000 USD
CY2018Q2 us-gaap Liabilities
Liabilities
2430000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16882000 USD
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12011000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2375000 USD
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1489000 USD
CY2017Q4 us-gaap Long Term Investments
LongTermInvestments
0 USD
CY2018Q2 us-gaap Long Term Investments
LongTermInvestments
0 USD
CY2017Q2 us-gaap Loss On Contract Termination
LossOnContractTermination
2641000 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-4298000 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-11304000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
34000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
7986000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6520000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4286000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4888000 USD
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2727000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4819000 USD
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2390000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4680000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2711000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-4772000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2420000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-4727000 USD
CY2017Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
268000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
448000 USD
CY2018Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
272000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
512000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
244000 USD
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
208000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
109000 USD
CY2018Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
98000 USD
CY2017Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2018Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-9000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-14000 USD
CY2017Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0 USD
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-10000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-14000 USD
CY2017Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 USD
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 USD
CY2017Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
18000 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
50000 USD
CY2018Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
15000 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
33000 USD
CY2017Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2000 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
3000 USD
CY2018Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
45000 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
80000 USD
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-16000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-47000 USD
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
30000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
47000 USD
CY2017Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
317000 USD
CY2017Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1392000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2017Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1966000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2725000 USD
CY2017Q2 us-gaap Share Based Compensation
ShareBasedCompensation
399000 USD
CY2017 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1427000 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1826 shares
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1826 shares
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
818000 USD
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
311000 USD
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
378000 USD
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13097000 USD
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0 USD
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
1500000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
124000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1539000 USD
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1477000 USD
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
317000 USD
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
332000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-342753000 USD
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-347433000 USD
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
293000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
617000 USD
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
285000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
345000 USD
CY2016Q4 us-gaap Security Deposit
SecurityDeposit
307000 USD
CY2017Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1866000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3142000 USD
CY2018Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1452000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
663000 USD
CY2018Q2 us-gaap Share Based Compensation
ShareBasedCompensation
315000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
596000 USD
CY2017Q3 us-gaap Share Price
SharePrice
4.00
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2018Q2 us-gaap Short Term Investments
ShortTermInvestments
6486000 USD
CY2017Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
570784 shares
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
27500 shares
CY2017Q2 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
28700000 shares
CY2017Q2 us-gaap Stock Issued During Period Shares Stock Splits
StockIssuedDuringPeriodSharesStockSplits
2900000 shares
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
13502000 USD
yten Charge For Company Common Stock Match
ChargeForCompanyCommonStockMatch
46000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
9581000 USD
CY2017Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
10
CY2017Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
65000 USD
CY2018Q2 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
43000 USD
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2849069 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2844492 shares
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9991460 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9845902 shares
CY2017Q4 yten Accrued Commercial Manufacturing Current
AccruedCommercialManufacturingCurrent
489000 USD
CY2018Q2 yten Accrued Commercial Manufacturing Current
AccruedCommercialManufacturingCurrent
0 USD
yten Charge For Company Common Stock Match
ChargeForCompanyCommonStockMatch
70000 USD
CY2017Q2 yten Cost Of Revenue Research And Development Expenses
CostOfRevenueResearchAndDevelopmentExpenses
1138000 USD
yten Cost Of Revenue Research And Development Expenses
CostOfRevenueResearchAndDevelopmentExpenses
2247000 USD
CY2018Q2 yten Cost Of Revenue Research And Development Expenses
CostOfRevenueResearchAndDevelopmentExpenses
1253000 USD
yten Cost Of Revenue Research And Development Expenses
CostOfRevenueResearchAndDevelopmentExpenses
2347000 USD
yten Increase Decrease In Deferred Rent And Long Term Liabilities
IncreaseDecreaseInDeferredRentAndLongTermLiabilities
-553000 USD
yten Increase Decrease In Deferred Rent And Long Term Liabilities
IncreaseDecreaseInDeferredRentAndLongTermLiabilities
-64000 USD
CY2017Q4 yten Lease Incentive Payable Noncurrent
LeaseIncentivePayableNoncurrent
1005000 USD
CY2018Q2 yten Lease Incentive Payable Noncurrent
LeaseIncentivePayableNoncurrent
941000 USD
CY2017 yten Operating Leases Landlord Reimbursement For Lease Improvements
OperatingLeasesLandlordReimbursementForLeaseImprovements
889000 USD
CY2017 yten Operatingleaseslandlordreimbforleaseimprovementsadditionalpayments
Operatingleaseslandlordreimbforleaseimprovementsadditionalpayments
444000 USD
yten Private Placement Issuance Costs Incurred During Noncashor Partial Noncash Transaction
PrivatePlacementIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction
146000 USD
yten Private Placement Issuance Costs Incurred During Noncashor Partial Noncash Transaction
PrivatePlacementIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction
0 USD
yten Reversal Of Deferred Financing Costs Related To Purchase Agreement
ReversalOfDeferredFinancingCostsRelatedToPurchaseAgreement
-450000 USD
yten Reversal Of Deferred Financing Costs Related To Purchase Agreement
ReversalOfDeferredFinancingCostsRelatedToPurchaseAgreement
0 USD
CY2018Q2 yten Sharebased Compensation Arrangementby Sharebased Payment Award Increase Of Shares Authorized Percent Of Outstanding Shares Percent
SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent
0.05
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company&#8217;s investment policy which establishes a concentration limit per issuer.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of grant revenue and expenses during the reporting periods. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0001121702-18-000031-index-headers.html Edgar Link pending
0001121702-18-000031-index.html Edgar Link pending
0001121702-18-000031.txt Edgar Link pending
0001121702-18-000031-xbrl.zip Edgar Link pending
ex-101xytenx2018stockoptio.htm Edgar Link pending
ex-102x20180630.htm Edgar Link pending
ex-311x20180630.htm Edgar Link pending
ex-312x20180630.htm Edgar Link pending
ex-31x20180630.htm Edgar Link pending
ex-321x20180630.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
yten-20180630.xml Edgar Link completed
yten-20180630.xsd Edgar Link pending
yten-20180630x10q.htm Edgar Link pending
yten-20180630_cal.xml Edgar Link unprocessable
yten-20180630_def.xml Edgar Link unprocessable
yten-20180630_lab.xml Edgar Link unprocessable
yten-20180630_pre.xml Edgar Link unprocessable